Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with T(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Oct 13

PMID 34638381

Citations 5

Authors

Katia Todoerti

Elisa Taiana

Noemi Puccio

Vanessa Favasuli

Marta Lionetti

Ilaria Silvestris

Massimo Gentile

Pellegrino Musto

Fortunato Morabito

Umberto Gianelli

Niccolo Bolli

Luca Baldini

Antonino Neri

Domenica Ronchetti

Affiliations

Soon will be listed here.

Abstract

Mechanisms underlying the pathophysiology of primary Plasma Cell Leukemia (pPCL) and intramedullary multiple myeloma (MM) need to be further elucidated, being potentially relevant for improving therapeutic approaches. In such a context, the MM and pPCL subgroups characterized by t(11;14) deserve a focused investigation, as the presence of the translocation is mainly associated with sensitivity to venetoclax. Herein, we investigated a proprietary cohort of MM and pPCL patients, focusing on the transcriptional signature of samples carrying t(11;14), whose incidence increases in pPCL in association with an unfavorable outcome. In addition, we evaluated the expression levels of the BCL2-gene family members and of a panel of B-cell genes recently reported to be associated with sensitivity to venetoclax in MM. Moreover, transcriptional analysis of lncRNAs in the two clinical settings led to the identification of several differentially expressed transcripts, among which the SNGH6 deregulated lncRNA might be relevant in the pathogenesis and prognosis of pPCL with t(11;14). Overall, our data suggest that MMs and pPCLs with t(11;14) might be responsive to venetoclax based on different molecular programs, prompting further studies to elucidate better novel potential predictive biomarkers.

Citing Articles

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).

Cegledi A, Csukly Z, Fekete M, Kozma A, Szemlaky Z, Andrikovics H Pathol Oncol Res. 2023; 29:1611375.

PMID: 38025905 PMC: 10668022. DOI: 10.3389/pore.2023.1611375.

Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance.

Saldarriaga M, Darwiche W, Jayabalan D, Monge J, Rosenbaum C, Pearse R Front Oncol. 2022; 12:1020011.

PMID: 36387095 PMC: 9646612. DOI: 10.3389/fonc.2022.1020011.

A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors.

Raimondi V, Iannozzi N, Burroughs-Garcia J, Toscani D, Storti P, Giuliani N Explor Target Antitumor Ther. 2022; 3(4):463-479.

PMID: 36071980 PMC: 9446161. DOI: 10.37349/etat.2022.00095.

Genomics of Plasma Cell Leukemia.

Rojas E, Gutierrez N Cancers (Basel). 2022; 14(6).

PMID: 35326746 PMC: 8946729. DOI: 10.3390/cancers14061594.

The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells.

Papadhimitriou S, Terpos E, Liapis K, Pavlidis D, Marinakis T, Kastritis E Biomedicines. 2022; 10(2).

PMID: 35203419 PMC: 8869452. DOI: 10.3390/biomedicines10020209.

References

Gonsalves W, Buadi F, Kumar S . Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). Eur J Haematol. 2017; 100(2):215-217. DOI: 10.1111/ejh.12986. View

Gupta V, Ackley J, Kaufman J, Boise L . BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma. Blood Lymphat Cancer. 2021; 11:11-24. PMC: 7965688. DOI: 10.2147/BLCTT.S245191. View

Kumar S, Kaufman J, Gasparetto C, Mikhael J, Vij R, Pegourie B . Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017; 130(22):2401-2409. DOI: 10.1182/blood-2017-06-788786. View

Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile T, Le Gouill S . BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2015; 30(3):761-4. PMC: 4714955. DOI: 10.1038/leu.2015.184. View

Usmani S, Nair B, Qu P, Hansen E, Zhang Q, Petty N . Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia. 2012; 26(11):2398-405. PMC: 3426639. DOI: 10.1038/leu.2012.107. View

Ronchetti D, Todoerti K, Vinci C, Favasuli V, Agnelli L, Manzoni M . Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma. Cancers (Basel). 2020; 12(4). PMC: 7225964. DOI: 10.3390/cancers12040782. View

Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson J, Souers A . The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2013; 28(1):210-2. PMC: 3887407. DOI: 10.1038/leu.2013.216. View

Chang L, Yuan Y, Li C, Guo T, Qi H, Xiao Y . Upregulation of SNHG6 regulates ZEB1 expression by competitively binding miR-101-3p and interacting with UPF1 in hepatocellular carcinoma. Cancer Lett. 2016; 383(2):183-194. DOI: 10.1016/j.canlet.2016.09.034. View

Ronchetti D, Agnelli L, Taiana E, Galletti S, Manzoni M, Todoerti K . Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma. Oncotarget. 2016; 7(12):14814-30. PMC: 4924754. DOI: 10.18632/oncotarget.7442. View

10.

Todoerti K, Calice G, Trino S, Simeon V, Lionetti M, Manzoni M . Global methylation patterns in primary plasma cell leukemia. Leuk Res. 2018; 73:95-102. DOI: 10.1016/j.leukres.2018.09.007. View

11.

Tan J, Smith A, Ferreira da Silva M, Matthey-Doret C, Rueedi R, Sonmez R . cis-Acting Complex-Trait-Associated lincRNA Expression Correlates with Modulation of Chromosomal Architecture. Cell Rep. 2017; 18(9):2280-2288. DOI: 10.1016/j.celrep.2017.02.009. View

12.

Albarracin F, Fonseca R . Plasma cell leukemia. Blood Rev. 2011; 25(3):107-12. PMC: 3907188. DOI: 10.1016/j.blre.2011.01.005. View

13.

Nalghranyan S, Singh A, Schinke C . The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol. 2019; 95(2):E34-E35. DOI: 10.1002/ajh.25676. View

14.

Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K . Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). Am J Hematol. 2018; 94(1):E35-E37. DOI: 10.1002/ajh.25331. View

15.

Schinke C, Boyle E, Ashby C, Wang Y, Lyzogubov V, Wardell C . Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer J. 2020; 10(6):70. PMC: 7303180. DOI: 10.1038/s41408-020-0336-z. View

16.

Murakami K, Kikugawa S, Kobayashi Y, Uehara S, Suzuki T, Kato H . Olfactomedin-like protein OLFML1 inhibits Hippo signaling and mineralization in osteoblasts. Biochem Biophys Res Commun. 2018; 505(2):419-425. DOI: 10.1016/j.bbrc.2018.09.112. View

17.

Sigova A, Mullen A, Molinie B, Gupta S, Orlando D, Guenther M . Divergent transcription of long noncoding RNA/mRNA gene pairs in embryonic stem cells. Proc Natl Acad Sci U S A. 2013; 110(8):2876-81. PMC: 3581948. DOI: 10.1073/pnas.1221904110. View

18.

Rojas E, Corchete L, Mateos M, Garcia-Sanz R, Misiewicz-Krzeminska I, Gutierrez N . Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. Blood Cancer J. 2019; 9(12):90. PMC: 6868169. DOI: 10.1038/s41408-019-0253-1. View

19.

Musto P . Progress in the Treatment of Primary Plasma Cell Leukemia. J Clin Oncol. 2016; 34(18):2082-4. DOI: 10.1200/JCO.2016.66.6115. View

20.

Gutierrez N, Hernandez J, Garcia J, Canizo M, Gonzalez M, Hernandez J . Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia. 2001; 15(5):840-5. DOI: 10.1038/sj.leu.2402116. View